Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial
Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants. No unexpected adverse events were observed, and psychosocial functioning improved across the cohort.